Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Radiomic and clinical predictors of cachexia in non-small cell lung cancer patients treated with immunotherapy

View ORCID ProfileWei Mu, Evangelia Katsoulakis, Kenneth L. Gage, Chris J. Whelan, View ORCID ProfileMatthew B. Schabath, View ORCID ProfileRobert J. Gillies
doi: https://doi.org/10.1101/2020.10.08.20207415
Wei Mu
aDepartment of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wei Mu
Evangelia Katsoulakis
bJames A. Haley Veterans’ Hospital, Tampa, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth L. Gage
cDepartment of Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris J. Whelan
aDepartment of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew B. Schabath
dDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, U.S.A
eDepartment of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matthew B. Schabath
Robert J. Gillies
aDepartment of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert J. Gillies
  • For correspondence: Robert.Gillies@moffitt.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Cachexia is present in up to 50% of patients with cancer and may contribute to primary resistance to immunotherapy. Biomarkers to predict cachexia are urgently required for early intervention. Herein, we test the hypothesis that pre-treatment 18F-FDG-PET/CT-based radiomics can be used to predict cachexia and subsequently associated with clinical outcomes among patients with advanced non-small cell lung cancer (NSCLC) who are treated with immunotherapy.

Methods This retrospective multi-institution study included 210 patients with histologically confirmed stage IIIB-IV NSCLC who were treated with immune checkpoint blockade between June 2011 and August 2019. Baseline (pre-immunotherapy) PET/CT images of 175 patients from Moffitt Cancer Center were used to train (N=123) and test (N=52) a radiomics signature to predict cachexia, which was also used to predict durable clinical benefit (DCB), progression-free survival (PFS) and overall survival (OS) subsequently. An external cohort that enrolled 35 patients from James A. Haley Veterans’ Hospital (VA) was used to further validate the predictive and prognostic value of this signature.

Results A radiomics signature demonstrated cachexia prediction ability with areas under receiver operating characteristics curves (AUC) of 0.77 (95%CI:0.68-0.85), 0.75 (95%CI:0.60-0.86) and of 0.73 (95%CI:0.53-0.92) in the training, test and external VA cohorts, respectively. For the further investigation of prognostic value, this signature could identify the patients with DCB with AUC of 0.67 (95%CI:0.57-0.77), 0.66 (95%CI:0.51-0.81), and 0.72 (95%CI:0.54-0.89) in these three cohorts. Additionally, the PFS and OS were significantly shorter among patients with higher radiomics signature in all the three cohorts (p<0.05).

Conclusion Using PET/CT radiomics analysis, cachexia could be predicted before the start of the immunotherapy, making it possible to monitor the patients with a higher risk of cachexia and identify patients most likely to benefit from immunotherapy.

Competing Interest Statement

Robert J. Gillies declared a potential conflict with HealthMyne, Inc [Investor (major), Board of Advisors (uncompensated)]. Contents of this research do not represent the views of the Department of Veterans Affairs or the United States Government. The remaining authors declare no conflict of interest.

Funding Statement

This study was funded by U.S. Public Health Service research grant U01 CA143062 and R01 CA190105 (awarded to Dr. Gillies). This material includes work supported with resources and the use of facilities at the James A. Haley Veterans' Hospital.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board at the University of South Florida (USF) and the James A. Haley Veterans Hospital, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Disclosure: This paper is supported by U.S. Public Health Service research grant U01 CA143062 and R01 CA190105 (principal investigator Dr. Gillies). Robert James Gillies declared a potential conflict with HealthMyne, Inc [Investor, Board of Advisors]. The remaining authors declare no conflict of interest.

Data Availability

The PET/CT imaging data and clinical information are not publicly available for patient privacy purposes, but are available from the corresponding authors upon reasonable request (R.J.G).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 11, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Radiomic and clinical predictors of cachexia in non-small cell lung cancer patients treated with immunotherapy
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Radiomic and clinical predictors of cachexia in non-small cell lung cancer patients treated with immunotherapy
Wei Mu, Evangelia Katsoulakis, Kenneth L. Gage, Chris J. Whelan, Matthew B. Schabath, Robert J. Gillies
medRxiv 2020.10.08.20207415; doi: https://doi.org/10.1101/2020.10.08.20207415
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Radiomic and clinical predictors of cachexia in non-small cell lung cancer patients treated with immunotherapy
Wei Mu, Evangelia Katsoulakis, Kenneth L. Gage, Chris J. Whelan, Matthew B. Schabath, Robert J. Gillies
medRxiv 2020.10.08.20207415; doi: https://doi.org/10.1101/2020.10.08.20207415

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Radiology and Imaging
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (49)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (190)
  • Epidemiology (5216)
  • Forensic Medicine (3)
  • Gastroenterology (194)
  • Genetic and Genomic Medicine (750)
  • Geriatric Medicine (77)
  • Health Economics (212)
  • Health Informatics (694)
  • Health Policy (352)
  • Health Systems and Quality Improvement (223)
  • Hematology (98)
  • HIV/AIDS (162)
  • Infectious Diseases (except HIV/AIDS) (5816)
  • Intensive Care and Critical Care Medicine (356)
  • Medical Education (102)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (758)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (231)
  • Oncology (475)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (93)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (139)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (854)
  • Public and Global Health (1993)
  • Radiology and Imaging (344)
  • Rehabilitation Medicine and Physical Therapy (157)
  • Respiratory Medicine (283)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (75)
  • Surgery (108)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)